« previous next »
Pages: [1]

Author Topic: (ECTRIMS) MS therapy GNbAC1 promotes myelin rejuvenation, study shows  (Read 125 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9549
  • MS diagnosed 1980
  • Location: Pacific Northwest
Update on temelimab (GNbAC1)
« on: April 27, 2020, 08:52:50 pm »
Trials of GNbAC1 (temelimab) have been delayed due to the COVID-19 outbreak. Some information about it:


https://www.mstrust.org.uk/a-z/temelimab


About the postponement, from  Yahoo Finance News (April 26, 2020):


https://finance.yahoo.com/news/geneuro-financial-information-business-first-053000714.html



Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
160 Views 		Last post September 04, 2017, 09:29:59 pm
by agate
0 Replies
79 Views 		Last post November 20, 2017, 03:48:24 pm
by agate
0 Replies
52 Views 		Last post May 09, 2018, 04:42:45 pm
by agate
0 Replies
71 Views 		Last post April 19, 2019, 02:37:42 pm
by agate
0 Replies
51 Views 		Last post September 14, 2019, 06:56:51 pm
by agate